U.S. attorneys general urge the FDA to combat counterfeit versions of weight loss drugs developed by Eli Lilly (LLY) and Novo Nordisk (NVO). Read more here.

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog (insulin-aspart-szjj, Sanofi-Aventis U.S.) was approved as biosimilar to Novolog (Novo Nordisk) for improving blood sugar control for individuals with the condition,

Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's sales should be going down soon. This morning, the U.S. Food and Drug Administration (FDA) issued a "declaratory order" confirming the "resolution of shortages of semaglutide injection products

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders such as Him & Hers (HIMS). Read more here.

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a growing group of telehealth companies such as Hims & Hers that have built businesses around offering cheaper copies of the branded medications.

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration

FDA declares Wegovy (R) and Ozempic (R) shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses -- All doses of the only real FDA-approved semaglutide medicines are being continuously shipped,

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity treatments improve.

US FDA declares Wegovy & Ozempic shortage is over and that Novo Nordisk is fully meeting or exceeding nationwide demand for all doses: Plainsboro, New Jersey Monday, February 24,